Does the aldosterone: renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study

Login or register to view PDF.

Background: High blood pressure is an important determinant of cardiovascular disease risk. Treated hypertensives do not attain a risk level equivalent to normotensives. This may be a consequence of suboptimal blood pressure control to which indiscriminate use of antihypertensive drugs may contribute. Indeed the recent ALLHAT[1] study suggests that thiazides should be given first to virtually all hypertensives. Whether this is correct or whether different antihypertensive therapies should be targeted towards different patients is a major unresolved issue, which we address in this study.

The measurement of the ratio of aldosterone: renin is used to identify hypertensive subjects who may respond well to treatment with the aldosterone antagonist spironolactone. It is not known if subjects with a high ratio have aldosteronism or aldosterone-sensitive hypertension is debated but it is important to know whether spironolactone is superior to other diuretics such as bendroflumethiazide in this setting.

Methods/design: The study is a double-blind, randomised, crossover, controlled trial that will randomise 120 hypertensive subjects to 12 weeks treatment with spironolactone 50 mg once daily and 12 weeks treatment with bendroflumethiazide 2.5 mg once daily. The 2 treatment periods are separated by a 2-week washout period. Randomisation is stratified by aldosterone: renin ratio to include equal numbers of subjects with high and low aldosterone: renin ratios.

Primary Objective – To test the hypothesis that the aldosterone: renin ratio predicts the antihypertensive response to spironolactone, specifically that the effect of spironolactone 50 mg is greater than that of bendroflumethiazide 2.5 mg in hypertensive subjects with high aldosterone: renin ratios.

Secondary Objectives – To determine whether bendroflumethiazide induces adverse metabolic abnormalities, especially in subjects with high aldosterone: renin ratios and if baseline renin measurement predicts the antihypertensive response to spironolactone and/or bendrofluazide Discussion: The numerous deleterious effects of hypertension dictate the need for a systematic approach for its treatment. In spite of various therapies, resistant hypertension is widely prevalent. Among various factors, aldosteronism is an important cause of resistant hypertension and is now more commonly recognised. More significantly, hypertensives with primary aldosteronism are also exposed to various other deleterious effects of excess aldosterone. Hence treating hypertension with specific aldosterone antagonists may be a better approach in this group of patients. It may lead on to better blood pressures with fewer medications.


One approach to more effective antihypertensive control would be to target aldosterone antagonists towardspatients in whom these drugs are likely to work best. Hyperaldosteronism is characterised by excessive excretion of aldosterone with concomitant suppression of enin associated with hypertension. However, neither aldosterone excretion nor plasma renin activity alone has proved useful in screening for this condition for a variety of reasons. Hiramatsu and colleagues have suggested that the aldosterone: renin ratio may be a useful screening test2. Using the aldosterone: renin ratio to find possible cases, Gordon and colleagues reported that hyperaldosteronism was more common than suspected, with 8% of cases referred to his clinic having this condition3. A high aldosterone: renin ratio has been found in 15% of a UK hypertension clinic4 and the general community5. There is debate as to whether a raised ratio defines aldosteronism or whether it detects a subgroup of subjects with aldosterone-sensitive hypertension, although subjects ith a raised ratio do appear to have genetic differences from those who do not6. If further testing is undertaken, 94% of clinic subjects with a raised ratio did not suppress plasma aldosterone with salt loading, a test many regard as diagnostic4. However, salt-loading is not without risks7 and a simple blood test that was able to guide appropriate therapy is an attractive concept./>/>/>


  1. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Jama 2002, 288:2981-2997.
  2. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T: A screening test to identify aldosterone- producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981, 141:1589-1593.
  3. Gordon RD: Mineralocorticoid hypertension. Lancet 1994, 344:240-243.
  4. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM: High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000, 14:311-315.
  5. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM: Potentially high prevalence of primary aldosteronism in a primarycare population. Lancet 1999, 353:40.
  6. Lim PO, Macdonald TM, Holloway C, Friel E, Anderson NH, Dow E, Jung RT, Davies E, Fraser R, Connell JM: Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio. J Clin Endocrinol Metab 2002, 87:4398-4402.
  7. Lim PO, Farquharson CA, Shiels P, Jung RT, Struthers AD, MacDonald TM: Adverse cardiac effects of salt with fludrocortisone in hypertension. Hypertension 2001, 37:856-861.
  8. Young W: Incidence and workup of primary aldosteronism at the Mayo Clinic: ; Brisbane. ; 1999.
  9. Gordon R: Incidence and workup of primary aldosteronism: Greenslopes Hospital series: ; Brisbane. ; 1999.
  10. Van Heerden J A AFC: Outcomes of surgery for primary aldosteronism: an instituinal experience: ; Brisbane. ; 1999.
  11. Brown JJ, Davies DL, Ferriss JB, Fraser R, Haywood E, Lever AF, Robertson JI: Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br Med J 1972, 2:729-734.
  12. Ghose RP, Hall PM, Bravo EL: Medical management of aldosterone- producing adenomas. Ann Intern Med 1999, 131:105-108.
  13. Lim PO, Young WF, MacDonald TM: A review of the medical treatment of primary aldosteronism. J Hypertens 2001, 19:353-361.
  14. Adlin EV, Marks AD, Channick BJ: Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity. Arch Intern Med 1972, 130:855-858.
  15. Gwinup G, Steinberg T: Differential response to thiazides and spironolactone in primary aldosteronism. Arch Intern Med 1967, 120:436-443.
  16. Lim PO, Jung RT, MacDonald TM: Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 1999, 48:756-760.
  17. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC: Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001, 37:699-705.
  18. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG: Blood pressure measuring devices: recommendations of the European Society of Hypertension. Bmj 2001, 322:531-536.
  19. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr., Lerman A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948-954.
  20. Elming H, Holm E, Jun L, Torp-Pedersen C, Kober L, Kircshoff M, Malik M, Camm J: The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J 1998, 19:1391-1400.
  21. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, Baig W, Flapan AD, Cowley A, Prescott RJ, Neilson JM, Fox KA: Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998, 98:1510-1516.22. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
  22. Yee KM, Pringle SD, Struthers AD: Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001, 37:1800-1807.
  23. Farquharson CA, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594-597.
  24. Lim PO, Donnan PT, MacDonald TM: Aldosterone to renin ratio as a determinant of exercise blood pressure response in hypertensive patients. J Hum Hypertens 2001, 15:119-123.
  25. Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
  26. Flack JM, Peters R, Shafi T, Alrefai H, Nasser SA, Crook E: Prevention of hypertension and its complications: theoretical basis and guidelines for treatment. J Am Soc Nephrol 2003, 14:S92-8.
  27. Gandhi S, Santiesteban H: Resistant hypertension. Suggestions for dealing with the problem. Postgrad Med 1996, 100:97-102, 107-8.
  28. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315-318.
  29. Isles CG, Walker LM, Beevers GD, Brown I, Cameron HL, Clarke J, Hawthorne V, Hole D, Lever AF, Robertson JW: Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986, 4:141-156.
  30. Struthers AD: Aldosterone: cardiovascular assault. Am Heart J 2002, 144:S2-7.
  31. Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563-575.
  32. Sato A, Funder JW, Saruta T: Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999, 12:867-873.
  33. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
  34. Farquharson CA, Struthers AD: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an ldosterone-induced vasculopathy. Clin Sci (Lond) 2002, 103:425-431.
  35. Farquharson CA, Struthers AD: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002, 103:425-431.